Bundibugyo Virus Disease in 2026: Clinical and Public Health Responses

Pediatric Infectious Disease Journal · Published 2026-08-05 · DOI 10.1097/inf.0000000000005359

Authors (1)

Robert J. Leggiadro

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Leggiadro, R. (2026). Bundibugyo Virus Disease in 2026: Clinical and Public Health Responses. Pediatric Infectious Disease Journal. https://doi.org/10.1097/inf.0000000000005359

Related articles

• The Wild West: A Case of Bubonic Plague · Pediatric Infectious Disease Journal · 2026 · Same journal
• Definitive Cefmetazole Therapy for Pediatric ESBL-producing Enterobacterales Bacteremia · Pediatric Infectious Disease Journal · 2026 · Same journal
• Beyond the Needle: Can Diet, Exercise and Supplements Boost Immunity in Children? · Pediatric Infectious Disease Journal · 2026 · Same journal
• Varicella Zoster Virus Meningitis Mimicking Pseudotumor Cerebri Syndrome in an Immunocompetent Vaccinated Adolescent Without Rash or Meningeal Signs · Pediatric Infectious Disease Journal · 2026 · Same journal
• Determinants of Severity in Pediatric Viral Lower Respiratory Tract Diseases From Emergency Department Presentation to Hospital Course · Pediatric Infectious Disease Journal · 2026 · Same journal
• Clinical Features and Predictors of Severity in Children Hospitalized With Human Metapneumovirus: A Multicenter Italian Study · Pediatric Infectious Disease Journal · 2026 · Same journal
• Rhinovirus: Too Bad to Be True · Pediatric Infectious Disease Journal · 2026 · Same journal
• Burden of COVID-19 in Korean Children: A Retrospective Observational Study Using Real-world Data · Pediatric Infectious Disease Journal · 2026 · Same journal
• Severe Mycoplasma-induced Rash and Mucositis Mimicking Stevens–Johnson Syndrome Treated With Steroid Pulse Therapy: A Case Highlighting Diagnostic Challenges and Therapeutic Considerations · Pediatric Infectious Disease Journal · 2026 · Same journal
• Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections · Pediatric Infectious Disease Journal · 2026 · Same journal